Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Involvement of heat shock proteins in Candida albicans biofilm formation.

Becherelli M, Tao J, Ryder NS.

J Mol Microbiol Biotechnol. 2013;23(6):396-400. doi: 10.1159/000351619. Epub 2013 Aug 7.

PMID:
23942459
2.

Identification and evaluation of novel acetolactate synthase inhibitors as antifungal agents.

Richie DL, Thompson KV, Studer C, Prindle VC, Aust T, Riedl R, Estoppey D, Tao J, Sexton JA, Zabawa T, Drumm J, Cotesta S, Eichenberger J, Schuierer S, Hartmann N, Movva NR, Tallarico JA, Ryder NS, Hoepfner D.

Antimicrob Agents Chemother. 2013 May;57(5):2272-80. doi: 10.1128/AAC.01809-12. Epub 2013 Mar 11.

3.

An integrated approach for identification and target validation of antifungal compounds active against Erg11p.

Hoepfner D, Karkare S, Helliwell SB, Pfeifer M, Trunzer M, De Bonnechose S, Zimmerlin A, Tao J, Richie D, Hofmann A, Reinker S, Frederiksen M, Movva NR, Porter JA, Ryder NS, Parker CN.

Antimicrob Agents Chemother. 2012 Aug;56(8):4233-40. doi: 10.1128/AAC.06332-11. Epub 2012 May 21.

4.

Nonspecific effect of Mycograb on amphotericin B MIC.

Richie DL, Ghannoum MA, Isham N, Thompson KV, Ryder NS.

Antimicrob Agents Chemother. 2012 Jul;56(7):3963-4. doi: 10.1128/AAC.00435-12. Epub 2012 Apr 16.

5.

Biophysical investigation of the mode of inhibition of tetramic acids, the allosteric inhibitors of undecaprenyl pyrophosphate synthase.

Lee LV, Granda B, Dean K, Tao J, Liu E, Zhang R, Peukert S, Wattanasin S, Xie X, Ryder NS, Tommasi R, Deng G.

Biochemistry. 2010 Jun 29;49(25):5366-76. doi: 10.1021/bi100523c.

6.

Discontinued drugs in 2008: anti-infectives.

Ryder NS.

Expert Opin Investig Drugs. 2010 Jan;19(1):1-21. doi: 10.1517/13543780903473150.

PMID:
20001552
7.

In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.

Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS.

Antimicrob Agents Chemother. 2009 Sep;53(9):3777-81. doi: 10.1128/AAC.00026-09. Epub 2009 Jul 13.

8.

Discontinued drugs in 2007: anti-infectives.

Ryder NS.

Expert Opin Investig Drugs. 2009 Jan;18(1):1-11. doi: 10.1517/13543780802614920 . Review.

PMID:
19053877
9.

Discontinued drugs in 2006: anti-infectives.

Ryder NS.

Expert Opin Investig Drugs. 2007 Dec;16(12):1867-78. Review.

PMID:
18041997
10.

Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.

Dean CR, Narayan S, Richards J, Daigle DM, Esterow S, Leeds JA, Kamp H, Puyang X, Wiedmann B, Mueller D, Voshol H, van Oostrum J, Wall D, Koehn J, Dzink-Fox J, Ryder NS.

Antimicrob Agents Chemother. 2007 Mar;51(3):1004-10. Epub 2007 Jan 12.

12.

Chemical and biological investigations of beta-oligoarginines.

Seebach D, Namoto K, Mahajan YR, Bindschädler P, Sustmann R, Kirsch M, Ryder NS, Weiss M, Sauer M, Roth C, Werner S, Beer HD, Munding C, Walde P, Voser M.

Chem Biodivers. 2004 Jan;1(1):65-97.

PMID:
17191776
13.

Peptide deformylase inhibitors as potent antimycobacterial agents.

Teo JW, Thayalan P, Beer D, Yap AS, Nanjundappa M, Ngew X, Duraiswamy J, Liung S, Dartois V, Schreiber M, Hasan S, Cynamon M, Ryder NS, Yang X, Weidmann B, Bracken K, Dick T, Mukherjee K.

Antimicrob Agents Chemother. 2006 Nov;50(11):3665-73. Epub 2006 Sep 11.

14.

NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Ma S, Boerner JE, TiongYip C, Weidmann B, Ryder NS, Cooreman MP, Lin K.

Antimicrob Agents Chemother. 2006 Sep;50(9):2976-82.

15.

Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine.

Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS.

Antimicrob Agents Chemother. 2006 Jun;50(6):2234-6.

16.

A collaborative hit-to-lead investigation leveraging medicinal chemistry expertise with high throughput library design, synthesis and purification capabilities.

Yang X, Parker D, Whitehead L, Ryder NS, Weidmann B, Stabile-Harris M, Kizer D, McKinnon M, Smellie A, Powers D.

Comb Chem High Throughput Screen. 2006 Feb;9(2):123-30.

PMID:
16475970
17.

Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.

Kirkpatrick WR, Vallor AC, McAtee RK, Ryder NS, Fothergill AW, Rinaldi MG, Patterson TF.

Antimicrob Agents Chemother. 2005 Nov;49(11):4751-3.

18.

Antifungal agents.

Ryder NS.

IDrugs. 1999 Dec;2(12):1253-5.

PMID:
16113946
19.

Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.

Dean CR, Narayan S, Daigle DM, Dzink-Fox JL, Puyang X, Bracken KR, Dean KE, Weidmann B, Yuan Z, Jain R, Ryder NS.

Antimicrob Agents Chemother. 2005 Aug;49(8):3129-35.

20.

Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine.

Osborne CS, Leitner I, Favre B, Ryder NS.

Antimicrob Agents Chemother. 2005 Jul;49(7):2840-4.

21.

Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates.

Favre B, Ghannoum MA, Ryder NS.

Med Mycol. 2004 Dec;42(6):525-9.

PMID:
15682641
22.

Antifungal drug response in an in vitro model of dermatophyte nail infection.

Osborne CS, Leitner I, Favre B, Ryder NS.

Med Mycol. 2004 Apr;42(2):159-63.

PMID:
15124869
23.

Identification of novel potent bicyclic peptide deformylase inhibitors.

Molteni V, He X, Nabakka J, Yang K, Kreusch A, Gordon P, Bursulaya B, Warner I, Shin T, Biorac T, Ryder NS, Goldberg R, Doughty J, He Y.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1477-81.

PMID:
15006385
24.

Antibiotic and hemolytic activity of a beta2/beta3 peptide capable of folding into a 12/10-helical secondary structure.

Arvidsson PI, Ryder NS, Weiss HM, Gross G, Kretz O, Woessner R, Seebach D.

Chembiochem. 2003 Dec 5;4(12):1345-7. No abstract available.

PMID:
14661278
25.

Alpha-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents.

Jain R, Sundram A, Lopez S, Neckermann G, Wu C, Hackbarth C, Chen D, Wang W, Ryder NS, Weidmann B, Patel D, Trias J, White R, Yuan Z.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4223-8. Erratum in: Bioorg Med Chem Lett. 2004 May 3;14(9):2373-4.

PMID:
14623006
26.

In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine.

Osborne CS, Hofbauer B, Favre B, Ryder NS.

Antimicrob Agents Chemother. 2003 Nov;47(11):3634-6.

27.
30.

Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine.

Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA.

Antimicrob Agents Chemother. 2003 Jan;47(1):82-6.

32.

On the antimicrobial and hemolytic activities of amphiphilic beta-peptides.

Arvidsson PI, Frackenpohl J, Ryder NS, Liechty B, Petersen F, Zimmermann H, Camenisch GP, Woessner R, Seebach D.

Chembiochem. 2001 Oct 1;2(10):771-3. No abstract available.

PMID:
11948860
33.

Inhibition of chitin synthetase from Saccharomyces cerevisiae by a new UDP-GlcNAc analogue.

Behr JB, Gautier-Lefebvre I, Mvondo-Evina C, Guillerm G, Ryder NS.

J Enzyme Inhib. 2001;16(2):107-12.

PMID:
11342279
34.
35.

40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Ryder NS.

Expert Opin Investig Drugs. 2000 Dec;9(12):2973-5. No abstract available.

PMID:
11203448
36.

Synthesis of new (difluoromethylphosphono)azadisaccharides designed as bisubstrate analogue inhibitors for GlcNAc:beta-1,4 glycosyltransferases.

Gautier-Lefebvre I, Behr JB, Guillerm G, Ryder NS.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1483-6.

PMID:
10888338
37.

Activity of terbinafine against serious fungal pathogens.

Ryder NS.

Mycoses. 1999;42 Suppl 2:115-9.

PMID:
10865917
38.

An evaluation of the in vitro activity of terbinafine.

Jessup CJ, Ryder NS, Ghannoum MA.

Med Mycol. 2000 Apr;38(2):155-9.

PMID:
10817232
39.

In vitro comparison of terbinafine and itraconazole against Penicillium marneffei.

McGinnis MR, Nordoff NG, Ryder NS, Nunn GB.

Antimicrob Agents Chemother. 2000 May;44(5):1407-8.

40.

Activity of terbinafine against serious fungal pathogens.

Ryder NS.

Mycoses. 1999 Dec;42 Suppl 2:115-119. doi: 10.1111/j.1439-0507.1999.tb00026.x.

PMID:
29265602
41.
42.

In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.

Ryder NS, Wagner S, Leitner I.

Antimicrob Agents Chemother. 1998 May;42(5):1057-61.

43.

Fluvastatin enhances receptor-stimulated intracellular Ca2+ release in human keratinocytes.

Coutant KD, Wolff-Winiski B, Ryder NS.

Biochem Biophys Res Commun. 1998 Apr 17;245(2):307-12.

PMID:
9571146
44.

Bradykinin induces actin reorganization and enhances cell motility in HaCaT keratinocytes.

Coutant KD, Corvaïa N, Ryder NS.

Biochem Biophys Res Commun. 1997 Aug 18;237(2):257-61.

PMID:
9268696
46.
47.

Inhibition of protein prenylation down-regulates signalling by inflammatory mediators in human keratinocytes.

Alaei P, MacNulty EE, Ryder NS.

Biochem Biophys Res Commun. 1996 May 6;222(1):133-8.

PMID:
8630058
48.

Characterization of prenyl protein transferase enzymes in a human keratinocyte cell line.

MacNulty EE, Ryder NS.

Biochim Biophys Acta. 1996 Feb 9;1289(1):41-50.

PMID:
8605230
50.

Bradykinin upregulates immediate-early gene mRNA in human keratinocytes.

Coutant KD, Ryder NS.

Arch Dermatol Res. 1996;288(1):2-6.

PMID:
8750926

Supplemental Content

Loading ...
Support Center